BioCentury
ARTICLE | Translation in Brief

Pushing risk

GSK and SBP partner on neurodegenerative disease translational center

April 28, 2016 7:00 AM UTC

An uptick in funding from public and private sources and advances in neurodegeneration have laid the groundwork for GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Sanford Burnham Prebys Medical Discovery Institute to join forces and create a center dedicated to accelerating high-risk, high-reward translational research.

The partners cut the ribbon for their new SBP-GSK Center for Translational Neuroscience on April 20. Researchers from both institutions will work side by side in a lab on the Sanford Burnham Prebys campus to discover and validate new targets...